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Abstract
Corneal transplantation is among the most successful solid organ transplants. However, despite
low rejection rates of grafts in the ‘low-risk’ setting, rejection can be as high as 70% when grafted
into ‘high-risk’ recipient beds. Under normal homeostatic conditions, the avascular cornea
provides a unique environment that facilitates immune and angiogenic privilege. An imbalance in
pro-inflammatory, angiogenic and lymphangiogenic mediators leads to a breakdown in corneal
immune privilege with a consequent host response against the donor graft. Recent developments
in lamellar and endothelial keratoplasties have reduced the rates of graft rejection even more,
while providing improved visual outcomes. The corneal layer against which an immune response
is initiated, largely determines reversibility of the acute episode. While epithelial and stromal graft
rejection may be treated with topical corticosteroids with higher success, acute endothelial
rejection mandates a more aggressive approach to therapy due to the lack of regenerative capacity
of this layer. However, current immunosuppressive regimens come with the caveat of ocular and
systemic side effects, making prolonged aggressive treatment undesirable. With the advent of
biologics, efficacious therapies with a superior side effect profile are on the horizon. In our review
we discuss the mediators of ocular immune privilege, the roles of cellular and molecular immune
players in graft rejection, with a focus on human leukocyte antigen and antigen presenting cells.
Furthermore, we discuss the clinical risk factors for graft rejection and compare rates of rejection
in lamellar and endothelial keratoplasties to traditional penetrating keratoplasty. Lastly, we present
the current and upcoming measures of therapeutic strategies to manage and treat graft rejection,
including an overview of biologics and small molecule therapy.
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tIntroduction
Corneal transplantation is among the most prevalent and successful organ transplants
performed worldwide [1] with more than 65,000 corneas transplanted annually [2]. An
overwhelming majority of these surgeries are performed in the United States, summing to
46,684 procedures in 2012 alone [3]. Whilst first-time ‘low-risk’ graft recipients may
experience a success rate of 90% in the first two years without a need for systemic
immunosuppression or histocompatibility leukocyte antigen (HLA) matching [4,5], up to
70% face graft failure in the ‘high-risk’ setting of vascularized corneal beds or a previous
history of graft rejection [6]. In the past decade, there has been a change in surgical trends in
corneal transplantation, moving away from full-thickness grafts in all patients to lamellar
procedures in cases when specific layers are affected for corneal diseases that differentially
affect selective layers of the cornea [7–10]. Penetrating keratoplasty, which is a full-
thickness transplant procedure, has been surpassed in its rates of graft survival, rejection
reversibility, visual and long-term surgical outcomes by selective lamellar keratoplasties that
aim to only treat the affected corneal layer [11–16]. Although the cornea is an immune
privileged site, graft rejection may ensue following breakdown of its immune privilege, by
corneal neovascularization, inflammation, or trauma to the graft among several other factors
discussed herein. In this review we discuss the molecular and cellular perpetrators of
immune-mediated graft rejection with emphasis on the roles of corneal dendritic cells (DCs)
and the human leukocyte antigens; risk factors than can threaten corneal immune privilege,
inducing immune-mediated graft rejection; rejection rates associated with full-thickness and
lamellar keratoplasties; and both current and evolving therapeutics in the prophylaxis and
management of corneal graft rejection.
Mechanisms of Corneal Graft Rejection
Human leukocyte antigen (HLA)
All cells of individuals within a single species express surface polymorphic proteins known
as major histocompatibility complex (MHC) antigens, which differentiate one individual
from another. MHC genes are prolifically polymorphic with over 200 allelic variants,
therefore further increasing the odds of mismatched antigens between donor and host
corneas in allogeneic transplants, creating an optimal opportunity for graft rejection; these
antigens are thus colloquially termed “major transplantation antigens” [17]. Chromosome 6
bears a dense region of contiguous MHC genes. In humans, the genes which code for these
“major transplantation antigens” on chromosome 6 are called human leukocyte antigen
(HLA) genes [18]. MHC antigens can be classified into two distinct types. MHC type I
(MHC-I) is found on all nucleated cells of the body and platelets. In the cornea, MHC-I
antigens are expressed by corneal epithelial, stromal and endothelial cells. In humans, these
transmembrane glycoproteins are coded for by HLA-A, HLA-B and HLA-C genes. The
other category of MHC antigens is type II (MHC-II). MHC-II antigens are more selectively
expressed, and are limited to the cell surface of immunocompetent antigen-presenting cells
(APCs) such as DCs, macrophages and Langerhans cells [18,19]. These MHC antigens are
expressed by HLA-DQ, -DR and –DW genes in humans and are not constitutively expressed
in the center of an otherwise healthy cornea [20]. Foreign antigens are presented to naïve T
cells by APCs as processed peptides in the presence of MHC-II and co-stimulatory
molecules to program recognition of “non-self” antigens. Inflammation, interferon gamma
(IFN-γ) and surgery can induce expression of MHC-II antigens in the cornea.
Corneal DCs play a critical role in graft rejection through their ability to regulate T cell
responses to both self and foreign antigens in the donor button, based on molecular cues
received from the tissue microenvironment [21]. Antigen recognition and capture occur
through MHC class-II antigens on the surface of mature DCs. The majority of resident
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tcentral corneal DCs reside in a dormant, undifferentiated state, and are MHC-II negative
[22]. During an inflammatory insult, DCs traffic from the blood to the cornea where donor
alloantigens are captured and transported to secondary lymphoid organs for processing and
presentation to T cells, thereby modulating the T cell response.
The evidence on the benefit of class I HLA tissue matching in reducing allogeneic corneal
graft rejection is fairly conclusive with exclusion of the Collaborative Corneal
Transplantation Studies (CCTS) data, demonstrating a clear benefit of prolonged graft
survival in type I HLA-matched corneal transplant cases [5,23,24]. Unlike the defined
advantage of type I HLA matching, a consensus on the utility of type II HLA matching
remains controversial. HLA-DR matching between donor and recipient has generated a
spectrum of conflicting data ranging from facilitating a prolonged graft survival rate of 79%
in HLA-DR matched high-risk eyes [25], to no observable effects as reported by the CCTS
study and studies conducted by Japanese groups [5], and even proving detrimental to the
corneal button in some populations [26,27]. To date, the only randomized, double-blinded,
prospective, controlled clinical trial evaluating donor-recipient histocompatibility matching
and cross-matching on graft survival in high-risk corneal transplantation is the CCTS [5].
The study however failed to detect any beneficial effect of tissue matching on the rate of
graft failure, rate of graft rejections, or the rate of failure caused by rejection [5]. The two
main criticisms of the CCTS are: first, that it included patients with limbal stem cell
deficiency, which could have masked the beneficial effect of HLA matching, and second,
that it employed an intense steroid regimen that could have suppressed HLA expression.
Murine studies have provided a sound platform to advocate the utility of tissue matching in
human corneal transplantation to prevent sensitization of the host to donor MHC antigens
leading to reduced incidence of graft rejection [23]. HLA matching in a controlled setting
among normal-risk patients demonstrated a clear advantage in ensuring clear and rejection-
free corneas [24]. Despite the controversy regarding the therapeutic benefit of HLA
matching in preventing corneal graft rejection [5,28], several reports suggest an association
between HLA incompatibility and graft rejection, and consequently the advantage of HLA
tissue typing especially in high-risk patients [28–32]. It has been shown that actively
rejecting grafts are strongly associated with primed, donor HLA-class I-specific cytotoxic T
cells, making a strong case in favor of HLA-A and –B typing for high-risk transplant
patients [29,33–36]. Indeed, the greater the number of HLA-A and HLA-B mismatches, the
greater the risk of graft rejection [36–39].
Another class of cell-surface proteins are the minor histocompatibility antigens, which
unlike the MHC, are coded for throughout the genome at various loci. In order to be
recognized as non-self antigens, minor histocompatibility antigens must be processed by
host APCs and presented with MHC-II molecules. ABO blood antigens are a relevant
example of such antigens and found on corneal epithelial cells whose expression is increased
in graft rejection. The CCTS proposed that ABO matching may reduce the risk of allogeneic
graft rejection in high-risk corneal transplantation [5]. It also reported that ABO
incompatibility increased the adjusted risk of failure from any cause and failure from
rejection [26], with estimated rejection rates of 41% in the ABO incompatible group
compared to 31% in the compatible group. These findings are consistent with other studies
that indicate non-MHC antigens may play an important role in corneal allograft rejection
[26,40], and the fact that ABO blood group antigens are expressed by the corneal epithelium
as well [41]. The potential disadvantages of tissue matching in corneal transplantation
however do merit a discussion. ABO matching is relatively inexpensive, and about 70% of
donors and recipient pairs would be compatible by chance. In contrast, HLA matching may
be logistically more complicated; along with the long duration of finding a suitable donor,
there may be a significant economic burden associated with obtaining HLA-matched donor
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ttissues for high-risk patients, totaling to an additional USD 4 million per annum [26].
According to a mathematical model, waiting times were predicted to be 15 months for a zero
mismatch, and 9 months for a single HLA mismatch [36,42]. Overall, there appears to be
considerable benefit to tissue matching, especially in high-risk transplantation. In the wake
of the CCTS trial, a more carefully designed clinical trial may provide conclusive answers to
this query.
Corneal immune privilege
The concept of corneal immune privilege is entertained by observations of high survival
rates of allogeneic corneal grafts despite HLA mismatching between donor and host tissues.
It is the uniquely configured corneal anatomy and physiology of the anterior chamber that
evade a host immune response through low immunogenicity and generation of alloantigen
tolerance [18,19,43]. The cornea is a uniquely avascular tissue and free of lymphatics,
preventing direct access of the immune system to the cornea through lack of vasculature,
and barring free transport of antigens and APCs to T cell-rich secondary lymphoid organs
through absence of lymph vessels. Further, all layers of the cornea have low constitutive
expression of MHC-I and –II antigens, limiting immunogenicity to foreign antigens. Even
though DCs are present both in the central and peripheral cornea, they exist in an immature,
inactivated state, maintaining immune quiescence in a healthy cornea. The cornea expresses
many cell membrane-bound molecules that guard the cornea from immune-mediated
inflammation and induce apoptosis of immune effector cells. These molecules include
complement regulatory proteins (CRP), Fas ligand (FasL), MHC-Ib and tumor necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL). FasL (CD95L), a pro-apoptotic
molecule, is expressed by the corneal epithelium and endothelium. FasL serves to destroy
polymorphonuclear neutrophils (PMNs) and effector T cells that express its receptor Fas/
CD95, promoting immune quiescence while protecting against immune-mediated graft
rejection [44,45]. The corneal epithelium, stroma and cells of the ciliary body also express
programmed death ligand-1 (PD-L1), which upon interaction with its cognate receptor
(PD-1) on T cells leads to inhibition of T cell proliferative capacity, induction of apoptosis
and suppression of IFN-γ secretion [46], promoting graft survival [47,48]. Expression of
PD-1 by T cells is regulated by Notch signaling [49]. PD-1 inhibits T cell proliferation
though suppression of Ras and Akt signaling pathways which inhibit transcription of SKP2
leading to upregulation of transforming growth factor-beta (TGF-β)-specific transcription
factor Smad3, resulting in cell cycle arrest of T cells [50].
The anterior chamber is rich in soluble immunosuppressive factors such as TGF-β, alpha-
melanocyte stimulating hormone (α-MSH), calcitonin gene-related peptide (CGRP), CRP,
somatostatin (SOM), indoleamine dioxygenase (IDO), vasointestinal peptide (VIP) and
macrophage migration inhibitory factor (MIF), which inhibit T cell and complement
activation [18,51]. The most notable contribution is that of anterior chamber-associated
immune deviation (ACAID), an alloantigen-specific peripheral immune tolerance to
antigens in the anterior chamber, capable of deviating the systemic cytotoxic immune
response [52,53]. ACAID suppresses delayed-type hypersensitivity (DTH) response and
maintains humoral immunity, promoting graft survival [54,55]. Antigens within the anterior
chamber are recognized and processed by F4/80+ APCs that orchestrate allotolerance by
upregulating the expression of TGF-β with downregulation of the co-stimulatory molecule
CD40/CD40L and interleukin-12 (IL-12) [53,56,57]. Suppression of DTH is brought about
by migration of these APCs to the spleen through vascular elements in the trabecular
meshwork, and together with splenic accessory immune cells, alloantigen-specific tolerance
is achieved [58–60]. While the effect of ACAID on DTH is unequivocal, its impact on the
regulation of cytotoxic T lymphocytes (CTL) is more complex, being dictated by the nature
of the antigens present in the anterior chamber. Some groups have demonstrated that CTL
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tfunction remains intact through expression of CTL precursors and effectors in the spleen and
lymph nodes of animals inoculated with tumor cells in vitro [60,61], making the hypothesis
of a suppressed CTL response an unlikely explanation for tumor growth in ACAID. In
contrast, other groups that used a soluble antigen for intracameral inoculation observed
inhibition of antigen-specific CD8+ T cell responses, confirming the antigen-dependent
effect of ACAID on CTL [62–66]. Since CTL responses contribute to allogeneic corneal
graft rejection even though they are not known to be directed against MHC alloantigens
[67–70], the effect of ACAID on CTL function against MHC antigens and the involvement
of FoxP3+ regulatory T cells (Treg) in modulating CD8+ T cell function during ACAID
have been explored [71]. Both CD4+ T and CD8+ T cell populations in the spleen proliferate
upon MHC alloantigen-specific ACAID induction, however, once ACAID is expressed, the
percentages of these T cells decrease substantially, suggesting ACAID-mediated inhibition
of both CD4+ T and CD8+ T cell function. Therefore, we now know that solubility of the
antigen is not a necessary determinant of ACAID-mediated CTL immune suppression.
Therefore measures to promote ACAID-mediated inhibition of DTH and CTL could prove
beneficial in prolonging graft survival. Interestingly, while FoxP3+ regulatory T cells (Treg)
increase upon ACAID induction, they have not been shown to be directly involved in the
modulation of ACAID-mediated MHC alloantigen-specific T cell function and response
[71].
Immunology of Corneal Graft Rejection
Corneal graft rejection occurs when the host immune response is directed toward antigens in
the donor corneal button, leading to tissue destruction brought about by cells and mediators
of the innate and adaptive immune responses. An immune response may target any of the
main layers of the cornea selectively, or, in combination. Compromise of the corneal
epithelium and stroma may be reversible, but, rejection of the endothelium invariably results
in irreversible endothelial cells loss and may result in permanent graft failure, if not treated
judiciously [72]. Sensitization of the host to donor antigens forms the “afferent” arm, also
known as the induction phase of corneal allograft rejection. This allorecognition process is
orchestrated by APCs presenting donor antigens to naïve T cells in draining lymph nodes in
either a direct or indirect fashion [18]. The direct pathway constitutes presentation of donor
antigens to naïve T cells directly by donor APCs through non-self MHC-II recognition on
their surface, resulting in proliferation of direct alloreactive T effector cells [19]. In contrast,
the indirect pathway yields donor antigens to host APCs that travel the cornea, capture
donor antigens, and transport them to draining lymph nodes where antigen presentation
occurs through recognition of self MHC-II by naïve T cells [19]. While initially believed to
be a phenomenon brought about exclusively by the indirect pathway [67], accumulated
evidence indicates that both the direct and indirect pathways are implicated in the immune-
mediated rejection of orthotopic corneal allografts, especially in high-risk corneal beds with
higher immunogenicity and compromised immune privilege [73–78]. The cornea harbors
resident populations of the most potent bone marrow-derived epithelial and stromal APCs
[22,79], namely, DCs, which are pivotal to the modulation of corneal immunogenicity [80].
These resident DCs are uniformly immature and MHC-II low/negative in the corneal center,
but with a change in the microenvironment of the cornea from a quiescent to an
inflammatory state, as in corneal transplantation, they express MHC-II and other co-
stimulatory molecules, as well as increase in density [22,79,81,82]. More recently additional
subpopulations of corneal DCs have been identified, adding to the complexity of the corneal
immune system [83–86]. Once DCs undergo maturation, they express co-stimulatory
molecules such as CD80, CD86 and CD40 [81], as well as differential adhesion molecules,
that activate T cell receptors and induce T cell proliferation through concurrent release of
cytokines. Among such cytokines are IL-1, -6 and -12 released by the APCs [80].
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tLymph nodes serve as the priming hub for T cell allosensitization and activation, which then
drives the subsequent “efferent” arm, or the expression phase, of immune-mediated graft
rejection. It is this phase that results in the actual destruction of the graft, making lymph
nodes profoundly critical to the process of rejection [87]. In support of the importance of
draining lymph nodes in the rejection process, several murine studies have demonstrated that
cervical lymphadenectomy prior to orthotopic corneal transplantation yields near complete
graft acceptance along with suppressed allospecific DTH response, regardless of the pre-
operative risk [77,88]. Following sensitization and activation of naïve T cells, cytokines and
chemokines released induce proliferation and trafficking of these alloreactive T cells to the
cornea through expression of specific combinations of adhesion molecules [89].
Chemokines (chemotactic cytokines), are small-molecule-weight cytokines that modulate
recruitment of leukocytes and immune cells to the inflamed cornea [80,89]. Immune-
mediated damage to the graft begins with the release of cytokines, such as tumor necrosis
factor-alpha (TNF-α) and IL-1, secondary to the mechanical trauma of surgery. In the
setting of high-risk corneal transplantation, cytokines further induce the production of
various early chemokines. Overexpression of chemokines monocyte chemotactic protein-1
(MCP-1), chemokine C-C motif ligand 2 (CCL2), regulated on activation normal T cell
expressed and secreted (RANTES; CCL5), macrophage inflammatory protein (MIP),
MIP-1α (CCL3) and MIP-1β (CCL4) in acute graft rejection leads to additional recruitment
of APCs and T cells into the cornea [18,90–92].
Once the graft and infiltrating leukocytes release late chemokines, guidance of alloreactive T
cells towards the graft begins [19,93]. Alloreactive T cells then migrate to the cornea where
they recognize donor MHC antigens, and also induce the development of memory T cells so
that an immune response may be mounted against the same antigens upon re-exposure as in
the case of a re-graft [19]. The primary cellular mediators of graft rejection are CD8+ CTL,
and CD4+ T-helper (Th) lymphocytes, otherwise known as DTH cells. Even though the role
of CTL in corneal graft rejection remains somewhat controversial, they are believed to be
sufficient but not necessary for corneal graft rejection [69,94]. Based on the types of
cytokines secreted by Th lymphocytes, T cells can be further classified into Th1, Th2 and
the more recently discovered Th17 cells [95,96]. Th1 cells are largely considered to be the
primary effector cells in corneal graft rejection [19,97]. CD4+ Th1 cells secrete IL-2, IFN-
gamma and lymphotoxin, which lead to inflammation as an attack on the inciting antigen.
IL-2 is critical to a sustained immune response by its positive feedback on T and B cell
activation and proliferation. IFN-γ ensures that macrophages are activated at the site of
inflammation, and facilitates further expression of MHC-II antigens in the donor button.
Th17 cells on the other hand secrete IL-17, IL-21 and IL-22 [98]. TGF-β is the key
differentiation factor for Th17 cells, which acts in concert with IL-6 or IL-21 and IL-23
serves as a stabilizing factor for maintaining the Th17 lineage [99–103]. IL-1 signaling also
comes into play via IL-1β-mediated regulation of the dendritic cell-mediated Th17 cell
differentiation pathways and maintenance of cytokine expression in Th17 cells [104].
Interestingly, TGF-β is also an inducer of CD4+CD25+Foxp3+ Tregs [105]. Therefore,
generation of Th17 cells or CD4+CD25+Foxp3+ Tregs is largely dictated by the cytokine
milieu of the tissue microenvironment [99,106,107]. Murine studies demonstrate increased
expression of Th17 cells in the early stages of corneal allograft rejection followed by
predominance of a Th1 response in the late stage [108]. However, Th17 do not orchestrate
the corneal immune response in graft rejection independently. The role of IL-17 in graft
rejection is somewhat limited. While some studies using monoclonal antibodies against
IL-17 successfully demonstrate a moderate increase in murine corneal allograft survival
[109], IL-17 knockout studies in mice failed to show improved graft survival [108]. This has
been postulated to be as a result of an emerging Th2 response, which then mediates graft
rejection [109,110]. However, there still remains controversy regarding clearly defined
pathways given the complex interplay of immune cells in corneal allograft rejection. Murine
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tIFN-γ and IL-17 knockout studies have shown that even MHC-matched corneal allografts
are rejected in an IFN-γ- and IL-17-independent manner, suggesting mediators other than
the simplistic model of Th1, Th2 or Th17 pathways [111].
Risk Factors of Corneal Graft Rejection
Both host and donor factors may contribute to the development of immune-mediated graft
rejection. Among the most widely accepted and well-established risk factors for corneal
allograft rejection are: presence of stromal blood vessels in one or more quadrants of the
recipient cornea (high risk), with at least a 6 clock-hour distance between the two blood
vessels, corneal neovascularization after surgery, prior graft rejection episodes, pre-
operative glaucoma, young age, prior anterior segment surgery, active ocular inflammation,
ocular surface disease, herpes simplex keratitis, neurotrophic keratopathy, large and
eccentric grafts, and anterior synechiae [6,112–114].
Corneal Allograft Rejection
High-risk
A high-risk cornea is defined by the CCTS as one with two or more quadrants of deep
stromal vessels prior to surgery, or, one in which a prior graft has been rejected [5]. Presence
of stromal vascularization in all four corneal quadrants doubles the risk of rejection [5],
increases the severity of immune response against the graft [115–117], and reduces the time
taken to reject the graft [118]. Rejection rates increase from 14% in avascular or minimally
vascular corneas to 32% in the presence of preoperative stromal neovascularization [119].
The 2-year survival of grafts placed in high-risk corneas is less than 50% [1]. History of a
prior episode of immune-mediated graft rejection poses a significant threat to the new graft.
The CCTS reported a cumulative increase in the risk of rejection by a factor of 1.2 with
every successive re-graft [5]. Taking into account and normalizing for corneal
neovascularization, patients may have rejection rates of 40%, 68% and 80% after the first,
second and third re-grafts [118].
Low-risk
Based on the number of corneal quadrants with stromal vascularization, a low-risk transplant
is defined as a graft placed in a recipient bed that is avascular. The 2-year survival rate
associated with low-risk grafts is an impressive near 90% [1,120,121], maintaining survival
rates of 90% and 82% at 5 and 10 years post-transplant [122,123].
Endothelial, lamellar and penetrating keratoplasties
With the recent development of more sophisticated sutureless surgical techniques that
dissect and replace the selected layer of diseased cornea, lamellar and endothelial
keratoplasties have led to reduction in graft rejection rates and improved surgical and visual
outcomes [16,124].
Endothelial keratoplasty—Descemet’s stripping automated endothelial keratoplasty
(DSAEK) and Descemet’s membrane endothelial keratoplasty (DMEK) allow selective
removal of the diseased Descemet’s membrane and endothelium, without disturbing the
epithelium and much of the stroma [10,15]. This translates into shorter healing time, lower
graft rejection rates, and improved visual quality. In comparison with deep anterior lamellar
keratoplasty (DALK) and traditional, full-thickness penetrating keratoplasty (PK), patients
that undergo DSAEK report fewer anterior corneal higher-order aberrations (HOA) but
lower visual acuity [16,125]. DSAEK is especially beneficial for endothelial diseases such
as Fuchs’ endothelial corneal dystrophy (FECD) and pseudophakic bullous keratopathy
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t(PBK), where the disease may be limited to a single corneal layer and employing PKP for a
full-thickness graft is to invite unnecessary complications and prolong healing. Patients with
FECD suffer from low contrast sensitivity, and even in cases where DSAEK does not
objectively improve visual acuity, 88% of these patients had stark improvement in contrast
sensitivity (CS), which translated into improved perceived visual quality [126]. The
presentation of endothelial rejection in DSAEK is atypical in that a Khodadoust line is rarely
seen [127,128]. Due to the absence of donor epithelium and stroma, and lack of direct
contact of the endothelium with limbal vessels, DSAEK offers a low endothelial rejection
rate of 10%, and is usually responsive to topical steroids [129].
DMEK, a procedure that involves removal and replacement of the Descemet’s membrane
and endothelium has generally a better visual acuity outcome than DSAEK [15]. In addition
to improved visual acuity, DMEK offers lower endothelial immune reactions [127].
However, preparation of the donor button and attachment pose significant technical issues in
the practice of DMEK [15]. Although DMEK has clearly been shown to have long-term
graft survival in comparison to DSEK and PKP, a recent clinical report has shown no
statistically significant difference in the long-term graft survival rates between DSEK and
PKP [127].
Lamellar keratoplasty—A preferred procedure for stromal diseases with a healthy
endothelium is a technique called deep anterior lamellar keratoplasty (DALK), where the
stroma and epithelium are replaced leaving the host endothelium intact [2]. DALK boasts a
10-year stable graft survival rate of 99.3% with an 11% loss in endothelial cell density from
pre-operative levels [130]. In randomized clinical trials, DALK emerged superior to PKP in
its safety demonstrated through preserved endothelial cell density and normal intraocular
pressure, and comparable in visual function outcomes for visual acuity [11,131]. The
reported three-year cumulative incidence of irreversible rejection is 0% with DALK grafts,
and 5.2% in PKP, whereas the 3-year cumulative rate of a rejection episode is 10% in
DALK and 23% in PKP, further emphasizing superiority of DALK over PKP [132].
Therapies for Corneal Graft Rejection
Immunosuppressives
Topical corticosteroids—Topical corticosteroids are the mainstay of treatment in the
management of acute graft rejection and as post-operative prophylactic therapy for high-risk
transplant patients. Topical 1% prednisolone acetate is typically prescribed in acute graft
rejection. A commonly prescribed regimen involves 1% prednisolone acetate every 1–2
hours for the first few weeks with gradual tapering over several months. Surgeons may
maintain indefinite treatment with low-dose steroids [133]. For non-endothelial graft
rejection, topical steroids are advised up to six times a day, with tapered dosing over 6–8
weeks. For mild endothelial rejection, the frequency is increased to hourly, along with
application of a steroid ointment at night for 3 days, with tapered dosing over a week.
However, in severe endothelial rejection topical steroids are prescribed hourly in
combination with systemic steroid therapy. Topical steroid use may be advised indefinitely,
especially in high-risk patients [134]. As a result of continued corticosteroid use, these
patients usually suffer from cataract, glaucoma, impaired wound healing and become prone
to infectious keratitis. Synthetic analogues of corticosteroids such as 0.5% loteprednol
etabonate suspension may be a viable alternative for patients in need of indefinite
immunesuppression due to a safer profile in maintaining lower intraocular pressures [135].
Systemic corticosteroids—In cases of severe endothelial graft rejection that present
early, there is debate over the benefit of oral systemic steroids versus pulse therapy. In a
randomized clinical trial that evaluated the outcomes of topical corticosteroid therapy with
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teither 60 to 80 mg of oral methylprednisolone daily, or, a single intravenous pulse of 500
mg methylpredinosolone, it was observed that pulse therapy was superior oral
methylpredinoslone. While the graft survival rates were comparable between the two
groups, only 26.3% of the surviving grafts in the pulse therapy group went on to have a
second rejection episode in comparison to 66.7% of the grafts in the oral steroid group, with
added benefit to repeated pulse therapy [136,137]. Methylprednisolone pulse therapy may be
substituted with subconjunctival or posterior subtenon’s triamcinolone injections in
combination with topical steroids in the treatment of endothelial rejection [134,138,139].
Alternatively, intravenous dexamethasone, at a dose of 1 mg/kg in patients with severe
endothelial rejection can be used for severe rejection. Reversibility of graft rejection is
reported to be better with intravenous dexamethasone (72.3% vs. 45%) as observed in a
retrospective study comparing combination therapy of topical steroids with either
dexamethasone, or, methylprednisolone [140]. Chronic systemic corticosteroid use is
associated with complications such as osteoporosis, diabetes, and weight gain. Unless the
patient has co-morbid inflammatory disease, long-term oral corticosteroids in the absence of
topical immune suppression is not justified and neither does it render protective effects
towards graft survival.
Calcineurin inhibitors—Cyclosporine A (CsA) and tacrolimus have proven efficacious
to varying degrees in the treatment of graft rejection and management of high-risk patients
post-transplantation. They provide viable options for sustained immunosuppression as
djuvants to corticosteroids. Several groups have investigated the benefit of combination
therapy with topical steroids and topical CsA in the management of acute graft rejection and
as prophylactic therapy in high-risk patients following keratoplasty. The results of such
studies are mixed and controversial. A randomized controlled trial failed to demonstrate any
additional benefit of adding 0.05% topical CsA to 1% topical methylprednisolone acetate in
the treatment of acute endothelial graft rejection [141]. This study however, not only
included patients that were not truly high-risk, but also may have masked any beneficial
effect of topical CsA by using a remarkably high frequency dosing protocol of
methylprednisolone. On the other hand, case-control studies in a pediatric population noted
a perceivable advantage in rejection-free graft survival rate using 2% CsA in addition to
topical steroids than steroids alone (88.9% vs. 38.5%, p=0.046) in the management of post-
transplant rejection prophylaxis with the caveat that there was no long-term graft survival
benefit between the two groups [142]. In other reports, 2% topical CsA ensured graft clarity
for up to 16 months [143]. Systemic administration of CsA has proved more effective in the
management of high-risk patients after transplantation [144–146], than treating acute graft
rejection, with due consideration to be given to patient selection given the serious systemic
side effect profile of CsA therapy [147–149]. For patients in whom corticosteroids are
contraindicated, topical CsA (0.5%) may provide an efficacious alternative for post-
transplant management with maintenance of graft clarity in 88% of the patients, with a 12%
rejection rate [150].
Tacrolimus (FK-506), also a calineurin inhibitor and thus similar in its mechanisms of action
to CsA, can be used topically or systemically in the management of low- and high-risk
corneal transplantation. Randomized clinical trials have demonstrated that low-dose (0.06%)
topical tacrolimus at a frequency of thrice daily for 6 months proved superior to topical
steroids in preventing rejection episodes (100% vs. 84%) in low-risk patients following
corneal transplantation [151]. Likewise, a low dose of 0.03% tacrolimus ointment proved
sufficient for the reversal of acute graft rejection episodes in high-risk patients and
maintained clear grafts throughout the duration of therapy [152]. Systemic administration of
tacrolimus (2–12mg daily) is also beneficial in preventing and treating graft rejection in
high-risk patients post-procedure, with a clear graft survival of 65% [153,154].
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dehydrogenase (IMPDH), inhibits the de novo synthesis of DNA in T and B lymphocytes,
making these immune cells cytostatic. Randomized clinical trials testing MMF have
demonstrated that the efficacy of MMF in preventing graft rejection in high-risk patients is
comparable to that of CsA [155,156]. MMF can also be supplemented with topical steroids
in the prevention graft rejection among high-risk patients. The combination of MMF with
topical steroids proved superior to CsA with topical steroids in terms of the 3-year rejection-
free graft survival (72% vs. 60%, p=0.03) with clear graft survival (87% vs. 77%) and
necessitated shorter duration of therapy [144].
Current novel therapeutics
Angiogenesis and lymphangiogenesis—Corneal neovascularization is the strongest
determinant of graft rejection prior to transplantation and poses a challenge to reinstating
ocular immune privilege in the wake of corneal transplantation [157]. Patent vasculature
invites immune and inflammatory cells to the cornea, allowing for immune-mediated
interactions with the donor antigens, setting a stage for impending graft rejection.
Mechanical treatments to the blood vessels such as photoablation, diathermy and
cryotherapy require multiple visits and the results are temporary [158,159]. Given the
pivotal role of corneal avascularity in promoting graft survival, optimizing corneal
transparency is essential. Vascular endothelial growth factor (VEGF)-A and –C are potent
mediators of heme- and lymphangiogenesis, both of which are critical to maintaining
corneal transparency. Corneal avascularity is maintained by soluble VEGFR-1, by a VEGF
trap mechanism [160]. Suture-induced inflammation induces parallel growth of blood and
lymph vessels into the cornea (lymphangiogenesis) [161,162], thereby creating a free-flow
channel for the recruitment and migration of primed T cells into the graft, making it
imperative to address corneal heme- and lymphangiogenesis. While mechanical treatment of
neovessels requires repeated visits, delivery of molecular anti-angiogenic agents can
sustainably prime the cornea before transplantation and also regress post-transplantation
neovascularization. Subconjunctival injections of bevacizumab, a monoclonal anti-VEGF
antibody, have been shown to not only increase graft survival when delivered prior to
transplantation, but also regress blood and lymph vessels during graft rejection [163–168].
More recently, murine studies have proved the efficacy of sunitinib, a multi-target tyrosine
kinase inhibitor, in the regression of corneal heme- and lymphangiogenesis through
inhibition of VEGF-A, VEGF-C and F4/80+ cell recruitment [169]. Antisesnse technology
has recently attracted attention with the application of morpholine oligonucleotides
(morpholinos) to silence or upregulate genes of interest. Morpholinos that induce expression
of the soluble form of VEGFR-1 have successfully demonstrated increased graft survival in
rodent models following subconjunctival delivery resulting in inhibition of both heme- and
lymphangiogenesis [170].
Immune cell trafficking—Adhesion molecules mediate trafficking of immune cells to
from the lymph nodes towards sites of inflammation such as the graft. Animal studies of
transplant rejection among various conditions of allodisparity and expression of intercellular
adhesion molecule 1 (ICAM-1) in transgenic mouse models revealed that deficiency of
ICAM-1 lead to significant improvement in graft survival in MHC-mismatched grafts,
suggesting the role of ICAM-1 in allosensitization of T cells to MHC antigens [171]. Other
promising targets for inhibition of corneal graft rejection are leukocyte function antigen-1
(LFA-1) and very late antigen-1 and 4 (VLA-1, VLA-4) [172,173].
Lymphocytes—Rapamycin (sirolimus), an inhibitor of a serine-threonine protein kinase,
mammalian target of rapamycin complex-1 (mTORC1), inhibitis effector T cell proliferation
and activation without compromising the function of regulatory T cells. In an open-label
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tstudy, rapamycin has been shown to have a 1-year rejection prevention rate of 78% and was
comparable in its efficacy to MMF in the management of high-risk transplant patients [174].
MMF and rapamycin may also be used in combination to prolong corneal graft survival in
high-risk patients [175], however, caution should be exercised before administering this
drug, alone or in combination with other immunosuppressives given its systemic toxicity
profile.
Another evolving approach to regulating effector T cell response is by delivering
monoclonal antibodies against T cell antigens. Monoclonal antibodies to CD3 and CD6 can
successfully treat episodes of acute graft rejection when delivered intracamerally [176,177].
Daclizumab and basiliximab both target the IL-2 receptor expressed on activated T cells to
inhibit T cell proliferation. Monoclonal antibodies may be combined with
immunosuppressives such as CsA in the management of high-risk transplant patients. One
such study investigated the utility of basiliximab and CsA in high-risk keratoplasty patients.
None of the patients suffered immune-mediated rejection edpisodes and maintained clear
grafts for up to a duration of 25 months [178]. When used as monotherapy, basiliximab
shows lower efficacy than CsA in preventing and treating graft rejection episodes following
high-risk keratoplasty. Patients that received basiliximab had a 40% rejection rate, and 50%
of the rejected grafts lead to graft failure [179]. Nevertheless, in terms of safety, none of the
patients developed side effects with use of this monoclonal antibody.
Co-Stimulatory blockade—Activated T cells are critical to immune-mediated graft
destruction. Complete and effective activation of T cells is contingent upon binding of T cell
receptor/CD3 with MHC molecules on APCs, and interaction of T cell co-stimulatory
molecule CD28 with B7 antigens on APCs (CD80 and CD86) [180]. Cytotoxic T-
Lymphocyte Antigen 4 protein (CTLA4-Ig), a fusion protein that competitively inhibits the
binding of B7 antigens with CD28, inhibits the activation of T cells and has been shown to
prolong corneal allograft survival after systemic injections or gene delivery to the corneal
epithelium [181,182]. Systemic administration of anti-CD28 monoclonal antibody or local
administration of non-functional CTLA4-Ig in rats, has also demonstrated prolonged graft
survival [183]. Moreover, incubation of rabbit donor cornea with CTLA4-Ig, prior to
grafting, enhances allograft survival in high-risk but not low-risk corneal transplantation
[184]. Furthermore, blockade of CD40–CD154 pathway by the use of anti-CD 154
monoclonal antibody has been shown to prevent corneal allograft rejection and promote the
acceptance in 100% of low-risk and in over 90% of high-risk grafts after systemic injections,
and to a lesser degree with topical use [185,186]. The role of both host and donor PD-L1 has
recently been demonstrated in corneal transplantation [47], blockade of which led to
enhanced graft survival [187]. Given the promise of localized, targeted therapy with a safe
side effect profile, treatment with biologics is promising for the future management of
corneal graft rejection.
Summary and Future Directions
The pathophysiology of corneal allograft rejection is highly complex and still, in part,
elusive. Nevertheless, significant advances have been made over the past several decades in
our understanding of the mechanisms of corneal graft rejection. Investigations probing into
the mechanisms and dissecting immune cell signaling and trafficking pathways are needed
to further unravel the cellular and molecular mediators in corneal graft rejection.
Development of targeted biological therapy in the future may provide new avenues in the
treatment of corneal graft rejection with much safer side effect profiles and sustained
therapeutic effects at lower doses. Further, the prospect of modulating immune cell activity
through the use of morpholine oligonucleoitides, RNA interference and targeted microRNAs
could be promising toward immunotherapy with minimal off-target effects. With the
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tdevelopment of new cellular and molecular therapeutic approaches, meticulous clinical trials
may then be designed to test their clinical utility. Currently, there is paucity of randomized
controlled trials in corneal transplantation research, making conclusions about the safety and
efficacy of treatment regimens limited.
Acknowledgments
Support
This work was supported by a career development grant K08-EY020575 (PH) from the National Institutes of
Health, Bethesda, Maryland and MEEI Foundation. P.H. is also the recipient of a Career Development Award from
Research to Prevent Blindness.
References
1. Streilein JW, Yamada J, Dana MR, Ksander BR. Anterior chamber-associated immune deviation,
ocular immune privilege, and orthotopic corneal allografts. Transplant Proc. 1999; 31:1472–1475.
[PubMed: 10330973]
2. Faraj LA, Hashmani K, Khatib T, Al-Aqaba M, Dua HS. The changing face of corneal graft
rejection. Br J Ophthalmol. 2012; 96:1049–1050. [PubMed: 22544532]
3. EBAA. Protecting Sight Worldwide- 2013 EBAA Year in Review. Washington, DC: Moire
Marketing Partners; 2013. p. 42
4. Niederkorn JY. High-risk corneal allografts and why they lose their immune privilege. Curr Opin
Allergy Clin Immunol. 2010; 10:493–497. [PubMed: 20689406]
5. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility
matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies
Research Group. Arch Ophthalmol. 1992; 110:1392–1403. [PubMed: 1417537]
6. Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, et al. Risk factors for corneal graft
failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal
Transplantation Studies Research Group. Ophthalmology. 1994; 101:1536–1547. [PubMed:
8090456]
7. Unal M, Arslan OS, Atalay E, Mangan MS, Bilgin AB. Deep anterior lamellar keratoplasty for the
treatment of stromal corneal dystrophies. Cornea. 2013; 32:301–305. [PubMed: 22790186]
8. Baradaran-Rafii A, Eslani M, Sadoughi MM, Esfandiari H, Karimian F. Anwar versus Melles deep
anterior lamellar keratoplasty for keratoconus: a prospective randomized clinical trial.
Ophthalmology. 2013; 120:252–259. [PubMed: 23084124]
9. Wang J, Zhao G, Xie L, Chen M, Zhao J. Therapeutic effect of deep anterior lamellar keratoplasty
for active or quiescent herpetic stromal keratitis. Graefes Arch Clin Exp Ophthalmol. 2012;
250:1187–1194. [PubMed: 22349979]
10. Terry MA, Ousley PJ. Replacing the endothelium without corneal surface incisions or sutures: the
first United States clinical series using the deep lamellar endothelial keratoplasty procedure.
Ophthalmology. 2003; 110:755–764. [PubMed: 12689898]
11. Shimazaki J, Shimmura S, Ishioka M, Tsubota K. Randomized clinical trial of deep lamellar
keratoplasty vs. penetrating keratoplasty. Am J Ophthalmol. 2002; 134:159–165. [PubMed:
12140020]
12. Borderie VM, Sandali O, Bullet J, Gaujoux T, Touzeau O, et al. Long-term results of deep anterior
lamellar versus penetrating keratoplasty. Ophthalmology. 2012; 119:249–255. [PubMed:
22054997]
13. Guilbert E, Bullet J, Sandali O, Basli E, Laroche L, et al. Long-term rejection incidence and
reversibility after penetrating and lamellar keratoplasty. Am J Ophthalmol. 2013; 155:560–569.
[PubMed: 23218931]
14. Kawashima M, Kawakita T, Den S, Shimmura S, Tsubota K, et al. Comparison of deep lamellar
keratoplasty and penetrating keratoplasty for lattice and macular corneal dystrophies. Am J
Ophthalmol. 2006; 142:304–309. [PubMed: 16876513]
Qazi and Hamrah Page 12
J Clin Cell Immunol. Author manuscript; available in PMC 2014 March 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t15. Price MO, Giebel AW, Fairchild KM, Price FW Jr. Descemet’s membrane endothelial
keratoplasty: prospective multicenter study of visual and refractive outcomes and endothelial
survival. Ophthalmology. 2009; 116:2361–2368. [PubMed: 19875170]
16. Koh S, Maeda N, Nakagawa T, Nishida K. Quality of vision in eyes after selective lamellar
keratoplasty. Cornea. 2012; 31:S45–S49. [PubMed: 23038035]
17. Complete sequence and gene map of a human major histocompatibility complex. The MHC
sequencing consortium. Nature. 1999; 401:921–923. [PubMed: 10553908]
18. Chong EM, Dana MR. Graft failure IV. Immunologic mechanisms of corneal transplant rejection.
Int Ophthalmol. 2008; 28:209–222. [PubMed: 17673946]
19. Streilein JW. Immunobiology and immunopathology of corneal transplantation. Chem Immunol.
1999; 73:186–206. [PubMed: 10590580]
20. Niederkorn JY. Mechanisms of corneal graft rejection: the sixth annual Thygeson Lecture,
presented at the Ocular Microbiology and Immunology Group meeting, October 21, 2000. Cornea.
2001; 20:675–679. [PubMed: 11588415]
21. Qazi, Y.; Turhan, A.; Hamrah, P. Trafficking of Immune Cells in the Cornea and Ocular Surface.
In: Rumelt, DS., editor. Advances in Ophthalmology. InTech Publisher; 2012. p. 568
22. Hamrah P, Zhang Q, Liu Y, Dana MR. Novel characterization of MHC class II-negative
population of resident corneal Langerhans cell-type dendritic cells. Invest Ophthalmol Vis Sci.
2002; 43:639–646. [PubMed: 11867578]
23. Vitova A, Kuffová L, Klaska IP, Holan V, Cornall RJ, et al. The high-risk corneal regraft model: a
justification for tissue matching in humans. Transpl Int. 2013; 26:453–461. [PubMed: 23398177]
24. Reinhard T, Böhringer D, Enczmann J, Kögler G, Mayweg S, et al. HLA class I and II matching
improves prognosis in penetrating normal-risk keratoplasty. Dev Ophthalmol. 2003; 36:42–49.
[PubMed: 12494679]
25. Baggesen K, Lamm LU, Ehlers N. Significant effect of high-resolution HLA-DRB1 matching in
high-risk corneal transplantation. Transplantation. 1996; 62:1273–1277. [PubMed: 8932271]
26. Sano Y, Ksander BR, Streilein JW. Minor H, rather than MHC, alloantigens offer the greater
barrier to successful orthotopic corneal transplantation in mice. Transpl Immunol. 1996; 4:53–56.
[PubMed: 8762011]
27. Bradley BA, Vail A, Gore SM, Rogers CA, Armitage WJ, et al. Negative effect of HLA-DR
matching on corneal transplant rejection. Transplant Proc. 1995; 27:1392–1394. [PubMed:
7878924]
28. Hill JC, Creemers PC. An adverse matching effect for the HLA-B locus in corneal transplantation.
Transpl Int. 1997; 10:145–149. [PubMed: 9090002]
29. Batchelor JR, Casey TA, Werb A, Gibbs DC, Prasad SS, et al. HLA matching and corneal grafting.
Lancet. 1976; 1:551–554. [PubMed: 55836]
30. Kissmeyer-Nielsen F, Ehlers N. Corneatransplantation and matching for HLA-A and B. Scand J
Urol Nephrol Suppl. 1977; 42:44–45. [PubMed: 356220]
31. Foulks GN, Sanfilippo FP, Locascio JA 3rd, MacQueen JM, Dawson DV. Histocompatibility
testing for keratoplasty in high-risk patients. Ophthalmology. 1983; 90:239–244. [PubMed:
6346199]
32. Gore SM, Vail A, Bradley BA, Rogers CA, Easty DL, et al. HLA-DR matching in corneal
transplantation. Systematic review of published evidence. Corneal Transplant Follow-up Study
Collaborators. Transplantation. 1995; 60:1033–1039. [PubMed: 7491677]
33. Roelen DL, van Beelen E, van Bree SP, van Rood JJ, Völker-Dieben HJ, et al. The presence of
activated donor HLA class I-reactive T lymphocytes is associated with rejection of corneal grafts.
Transplantation. 1995; 59:1039–1042. [PubMed: 7709440]
34. Boisjoly HM, Roy R, Bernard PM, Dubé I, Laughrea PA, et al. Association between corneal
allograft reactions and HLA compatibility. Ophthalmology. 1990; 97:1689–1698. [PubMed:
2087300]
35. Völker-Dieben HJ, Schreuder GM, Claas FH, Doxiadis II, Schipper RF, et al. Histocompatibility
and corneal transplantation. Dev Ophthalmol. 2003; 36:22–41. [PubMed: 12494678]
Qazi and Hamrah Page 13
J Clin Cell Immunol. Author manuscript; available in PMC 2014 March 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t36. Böhringer D, Reinhard T, Duquesnoy RJ, Böhringer S, Enczmann J, et al. Beneficial effect of
matching at the HLA-A and -B amino-acid triplet level on rejection-free clear graft survival in
penetrating keratoplasty. Transplantation. 2004; 77:417–421. [PubMed: 14966417]
37. Reinhard T, Böhringer D, Enczmann J, Kögler G, Mayweg S, et al. Improvement of graft
prognosis in penetrating normal-risk keratoplasty by HLA class I and II matching. Eye (Lond).
2004; 18:269–277. [PubMed: 15004576]
38. Bartels MC, Doxiadis II, Colen TP, Beekhuis WH. Long-term outcome in high-risk corneal
transplantation and the influence of HLA-A and HLA-B matching. Cornea. 2003; 22:552–556.
[PubMed: 12883350]
39. Beekhuis WH, Bartels M, Doxiadis II, van Rij G. Degree of compatibility for HLA-A and -B
affects outcome in high-risk corneal transplantation. Dev Ophthalmol. 2003; 36:12–21. [PubMed:
12494677]
40. Streilein JW, Arancibia-Caracamo C, Osawa H. The role of minor histocompatibility alloantigens
in penetrating keratoplasty. Dev Ophthalmol. 2003; 36:74–88. [PubMed: 12494683]
41. Treseler PA, Foulks GN, Sanfilippo F. Expression of ABO blood group, hematopoietic, and other
cell-specific antigens by cells in the human cornea. Cornea. 1985; 4:157–168. [PubMed: 3916388]
42. Böhringer D, Reinhard T, Enczmann J, Godehard E, Sundmacher R. Individual analysis of
expected time on the waiting list for HLA-matched corneal grafts. Dev Ophthalmol. 2003; 36:50–
55. [PubMed: 12494680]
43. Yamada J, Streilein JW. Induction of anterior chamber-associated immune deviation by corneal
allografts placed in the anterior chamber. Invest Ophthalmol Vis Sci. 1997; 38:2833–2843.
[PubMed: 9418737]
44. Yamagami S, Kawashima H, Tsuru T, Yamagami H, Kayagaki N, et al. Role of Fas-Fas ligand
interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation.
1997; 64:1107–1111. [PubMed: 9355824]
45. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, et al. CD95 ligand (FasL)-induced apoptosis is
necessary for corneal allograft survival. J Clin Invest. 1997; 99:396–402. [PubMed: 9022072]
46. Liechtenstein T, Dufait I, Bricogne C, Lanna A, Pen J, et al. PD-L1/PD-1 Co-Stimulation, a Brake
for T cell Activation and a T cell Differentiation Signal. J Clin Cell Immunol. 2012; S12:006.
[PubMed: 23525238]
47. Shen L, Jin Y, Freeman GJ, Sharpe AH, Dana MR. The function of donor versus recipient
programmed death-ligand 1 in corneal allograft survival. J Immunol. 2007; 179:3672–3679.
[PubMed: 17785803]
48. Yang W, Li H, Chen PW, Alizadeh H, He Y, et al. PD-L1 expression on human ocular cells and its
possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci.
2009; 50:273–280. [PubMed: 18791172]
49. Mathieu M, Cotta-Grand N, Daudelin JF, Thébault P, Labrecque N. Notch signaling regulates
PD-1 expression during CD8(+) T-cell activation. Immunol Cell Biol. 2013; 91:82–88. [PubMed:
23070399]
50. Patsoukis N, Sari D, Boussiotis VA. PD-1 inhibits T cell proliferation by upregulating p27 and p15
and suppressing Cdc25A. Cell Cycle. 2012; 11:4305–4309. [PubMed: 23032366]
51. Jiang L, He H, Yang P, Lin X, Zhou H, et al. Splenic CD8+ T cells secrete TGF-beta1 to exert
suppression in mice with anterior chamber-associated immune deviation. Graefes Arch Clin Exp
Ophthalmol. 2009; 247:87–92. [PubMed: 18797912]
52. Stein-Streilein J, Streilein JW. Anterior chamber associated immune deviation (ACAID):
regulation, biological relevance, and implications for therapy. Int Rev Immunol. 2002; 21:123–
152. [PubMed: 12424840]
53. Wilbanks GA, Streilein JW. Studies on the induction of anterior chamber-associated immune
deviation (ACAID) 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal
exists in the peripheral blood. J Immunol. 1991; 146:2610–2617. [PubMed: 1707912]
54. Streilein JW. Anterior chamber associated immune deviation: the privilege of immunity in the eye.
Surv Ophthalmol. 1990; 35:67–73. [PubMed: 2204129]
Qazi and Hamrah Page 14
J Clin Cell Immunol. Author manuscript; available in PMC 2014 March 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t55. Yao YF, Inoue Y, Miyazaki D, Hara Y, Shimomura Y, et al. Correlation of anterior chamber-
associated immune deviation with suppression of corneal epithelial rejection in mice. Invest
Ophthalmol Vis Sci. 1997; 38:292–300. [PubMed: 9040461]
56. Cousins SW, McCabe MM, Danielpour D, Streilein JW. Identification of transforming growth
factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci. 1991;
32:2201–2211. [PubMed: 2071334]
57. Takeuchi M, Alard P, Streilein JW. TGF-beta promotes immune deviation by altering accessory
signals of antigen-presenting cells. J Immunol. 1998; 160:1589–1597. [PubMed: 9469414]
58. Streilein JW, Niederkorn JY. Induction of anterior chamber-associated immune deviation requires
an intact, functional spleen. 1981. Ocul Immunol Inflamm. 2007; 15:187–194. [PubMed:
17613833]
59. Saban DR, Elder IA, Nguyen CQ, Smith WC, Timmers AM, et al. Characterization of intraocular
immunopathology following intracameral inoculation with alloantigen. Mol Vis. 2008; 14:615–
624. [PubMed: 18385797]
60. Niederkorn JY, Streilein JW. Alloantigens placed into the anterior chamber of the eye induce
specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and
helper T lymphocyte responses. J Immunol. 1983; 131:2670–2674. [PubMed: 6196396]
61. Ksander BR, Streilein JW. Analysis of cytotoxic T cell responses to intracameral allogeneic
tumors. Invest Ophthalmol Vis Sci. 1989; 30:323–329. [PubMed: 2492486]
62. Xu Y, Kapp JA. gammadelta T cells are critical for the induction of anterior chamber-associated
immune deviation. Immunology. 2001; 104:142–148. [PubMed: 11683953]
63. Xu Y, Kapp JA. Gammadelta T cells in anterior chamber-induced tolerance in CD8(+) CTL
responses. Invest Ophthalmol Vis Sci. 2002; 43:3473–3479. [PubMed: 12407158]
64. McKenna KC, Xu Y, Kapp JA. Injection of soluble antigen into the anterior chamber of the eye
induces expansion and functional unresponsiveness of antigen-specific CD8+ T cells. J Immunol.
2002; 169:5630–5637. [PubMed: 12421942]
65. McKenna KC, Anderson KM, Kapp JA. CD8+ T-cell tolerance induced by delivery of antigen to
the anterior chamber is not the result of de facto intravenous or mucosal administration of antigen.
Ocul Immunol Inflamm. 2005; 13:149–157. [PubMed: 16019674]
66. Hara Y, Okamoto S, Rouse B, Streilein JW. Evidence that peritoneal exudate cells cultured with
eye-derived fluids are the proximate antigen-presenting cells in immune deviation of the ocular
type. J Immunol. 1993; 151:5162–5171. [PubMed: 8228216]
67. Sano Y, Streilein JW, Ksander BR. Detection of minor alloantigen-specific cytotoxic T cells after
rejection of murine orthotopic corneal allografts: evidence that graft antigens are recognized
exclusively via the “indirect pathway”. Transplantation. 1999; 68:963–970. [PubMed: 10532535]
68. Sano Y, Ksander BR, Streilein JW. Analysis of primed donor-specific T cells in recipient mice
bearing orthotopic corneal allografts. Transplantation. 2000; 70:1302–1310. [PubMed: 11087144]
69. Hegde S, Niederkorn JY. The role of cytotoxic T lymphocytes in corneal allograft rejection. Invest
Ophthalmol Vis Sci. 2000; 41:3341–3347. [PubMed: 11006223]
70. Paunicka K, Chen PW, Niederkorn JY. Role of IFN-gamma in the establishment of anterior
chamber-associated immune deviation (ACAID)-induced CD8+ T regulatory cells. J Leukoc Biol.
2012; 91:475–483. [PubMed: 22180630]
71. Saban DR, Cornelius J, Masli S, Schwartzkopff J, Doyle M, et al. The role of ACAID and
CD4+CD25+FOXP3+ regulatory T cells on CTL function against MHC alloantigens. Mol Vis.
2008; 14:2435–2442. [PubMed: 19104677]
72. Claerhout I, Beele H, Kestelyn P. Graft failure: I. Endothelial cell loss. Int Ophthalmol. 2008;
28:165–173. [PubMed: 17508129]
73. Williams KA, Coster DJ. The immunobiology of corneal transplantation. Transplantation. 2007;
84:806–813. [PubMed: 17984831]
74. Dana MR, Qian Y, Hamrah P. Twenty-five-year panorama of corneal immunology: emerging
concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and
corneal transplant rejection. Cornea. 2000; 19:625–643. [PubMed: 11009315]
Qazi and Hamrah Page 15
J Clin Cell Immunol. Author manuscript; available in PMC 2014 March 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t75. Sano Y, Ksander BR, Streilein JW. Langerhans cells, orthotopic corneal allografts, and direct and
indirect pathways of T-cell allorecognition. Invest Ophthalmol Vis Sci. 2000; 41:1422–1431.
[PubMed: 10798658]
76. Boisgérault F, Liu Y, Anosova N, Dana R, Benichou G. Differential roles of direct and indirect
allorecognition pathways in the rejection of skin and corneal transplants. Transplantation. 2009;
87:16–23. [PubMed: 19136886]
77. Yamagami S, Amano S. Role of resident corneal leukocytes and draining cervical lymph nodes in
corneal allograft rejection. Cornea. 2003; 22:S61–S65. [PubMed: 14703709]
78. Huq S, Liu Y, Benichou G, Dana MR. Relevance of the direct pathway of sensitization in corneal
transplantation is dictated by the graft bed microenvironment. J Immunol. 2004; 173:4464–4469.
[PubMed: 15383577]
79. Hamrah P, Liu Y, Zhang Q, Dana MR. The corneal stroma is endowed with a significant number
of resident dendritic cells. Invest Ophthalmol Vis Sci. 2003; 44:581–589. [PubMed: 12556386]
80. Hamrah P, Dana MR. Corneal antigen-presenting cells. Chem Immunol Allergy. 2007; 92:58–70.
[PubMed: 17264483]
81. Hamrah P, Liu Y, Zhang Q, Dana MR. Alterations in corneal stromal dendritic cell phenotype and
distribution in inflammation. Arch Ophthalmol. 2003; 121:1132–1140. [PubMed: 12912691]
82. Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana MR. Draining lymph nodes of corneal transplant
hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive
dendritic cells derived from MHC class II-negative grafts. J Exp Med. 2002; 195:259–268.
[PubMed: 11805152]
83. Mayer WJ, Irschick UM, Moser P, Wurm M, Huemer HP, et al. Characterization of antigen-
presenting cells in fresh and cultured human corneas using novel dendritic cell markers. Invest
Ophthalmol Vis Sci. 2007; 48:4459–4467. [PubMed: 17898266]
84. Zheng, L.; von Andrian, UH.; Hamrah, P. Identification of Novel Subsets of Plasmacytoid and
Conventional Dendritic Cells in the Cornea. Florida, USA: Fort Lauderdale; 2010.
85. Hu, K.; Harris, D.; Yamaguchi, T.; Ghiasi, H.; von Andrian, UH., et al. The role of corneal
Plasmacytoid Dendritic Cells in acute herpes simplex virus infection. Washington, USA: Seattle;
2013.
86. Hattori T, Chauhan SK, Lee H, Ueno H, Dana R, et al. Characterization of Langerin-expressing
dendritic cell subsets in the normal cornea. Invest Ophthalmol Vis Sci. 2011; 52:4598–4604.
[PubMed: 21482644]
87. Yamagami S, Dana MR. The critical role of lymph nodes in corneal alloimmunization and graft
rejection. Invest Ophthalmol Vis Sci. 2001; 42:1293–1298. [PubMed: 11328742]
88. Yamagami S, Dana MR, Tsuru T. Draining lymph nodes play an essential role in alloimmunity
generated in response to high-risk corneal transplantation. Cornea. 2002; 21:405–409. [PubMed:
11973391]
89. Qazi, Y.; Turhan, A.; Hamrah, P. Trafficking of Immune Cells in the Cornea and Ocular Surface.
In: Dr Rumelt, S., editor. Advances in Ophthalmology. Rijeka: InTech; 2012. p. 79-104.
90. Yamagami S, Miyazaki D, Ono SJ, Dana MR. Differential chemokine gene expression in corneal
transplant rejection. Invest Ophthalmol Vis Sci. 1999; 40:2892–2897. [PubMed: 10549649]
91. Yamagami S, Hamrah P, Zhang Q, Liu Y, Huq S, et al. Early ocular chemokine gene expression
and leukocyte infiltration after high-risk corneal transplantation. Mol Vis. 2005; 11:632–640.
[PubMed: 16145544]
92. Yamagami S, Isobe M, Tsuru T. Characterization of cytokine profiles in corneal allograft with
anti-adhesion therapy. Transplantation. 2000; 69:1655–1659. [PubMed: 10836377]
93. Yamaguchi, T.; Hamrah, P. Immunotherapy of Ocular Surface Diseases and Graft Rejection. In:
Copland, R.; Afshari, NA., editors. Copland and Afshari’s Principles and Practice of Cornea. New
Delhi: Jaypee Brothers; 2013. p. 580-600.
94. Yamada J, Ksander BR, Streilein JW. Cytotoxic T cells play no essential role in acute rejection of
orthotopic corneal allografts in mice. Invest Ophthalmol Vis Sci. 2001; 42:386–392. [PubMed:
11157871]
Qazi and Hamrah Page 16
J Clin Cell Immunol. Author manuscript; available in PMC 2014 March 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t95. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, et al. Interleukin 17-producing
CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat
Immunol. 2005; 6:1123–1132. [PubMed: 16200070]
96. Park H, Li Z, Yang XO, Chang SH, Nurieva R, et al. A distinct lineage of CD4 T cells regulates
tissue inflammation by producing interleukin 17. Nat Immunol. 2005; 6:1133–1141. [PubMed:
16200068]
97. Hegde S, Beauregard C, Mayhew E, Niederkorn JY. CD4(+) T-cell-mediated mechanisms of
corneal allograft rejection: role of Fas-induced apoptosis. Transplantation. 2005; 79:23–31.
[PubMed: 15714165]
98. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in
inflammation. Immunity. 2008; 28:454–467. [PubMed: 18400188]
99. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. Reciprocal developmental pathways for the
generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441:235–238.
[PubMed: 16648838]
100. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, et al. Transforming growth
factor-beta induces development of the T(H)17 lineage. Nature. 2006; 441:231–234. [PubMed:
16648837]
101. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an
inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.
Immunity. 2006; 24:179–189. [PubMed: 16473830]
102. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, et al. IL-6 programs T(H)-17 cell
differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat
Immunol. 2007; 8:967–974. [PubMed: 17581537]
103. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, et al. IL-21 initiates an alternative pathway to
induce proinflammatory T(H)17 cells. Nature. 2007; 448:484–487. [PubMed: 17581588]
104. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, et al. Critical regulation of early Th17
cell differentiation by interleukin-1 signaling. Immunity. 2009; 30:576–587. [PubMed:
19362022]
105. Zheng SG, Wang JH, Koss MN, Quismorio F Jr, Gray JD, et al. CD4+ and CD8+ regulatory T
cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease
with a lupus-like syndrome. J Immunol. 2004; 172:1531–1539. [PubMed: 14734731]
106. Xu L, Kitani A, Fuss I, Strober W. Cutting edge: regulatory T cells induce CD4+CD25−Foxp3−
T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J
Immunol. 2007; 178:6725–6729. [PubMed: 17513718]
107. Chen L, Ahmed E, Wang T, Wang Y, Ochando J, et al. TLR signals promote IL-6/IL-17-
dependent transplant rejection. J Immunol. 2009; 182:6217–6225. [PubMed: 19414775]
108. Chen H, Wang W, Xie H, Xu X, Wu J, et al. A pathogenic role of IL-17 at the early stage of
corneal allograft rejection. Transpl Immunol. 2009; 21:155–161. [PubMed: 19358887]
109. Chen X, Zhao S, Tang X, Ge H, Liu P. Neutralization of mouse interleukin-17 bioactivity inhibits
corneal allograft rejection. Mol Vis. 2011; 17:2148–2156. [PubMed: 21850190]
110. Cunnusamy K, Chen PW, Niederkorn JY. IL-17 promotes immune privilege of corneal allografts.
J Immunol. 2010; 185:4651–4658. [PubMed: 20844197]
111. Yamada J, Hamuro J, Fukushima A, Ohteki T, Terai K, et al. MHC-matched corneal allograft
rejection in an IFN-gamma/IL-17-independent manner in C57BL/6 mice. Invest Ophthalmol Vis
Sci. 2009; 50:2139–2146. [PubMed: 19136699]
112. Boisjoly HM, Bernard PM, Dubé I, Laughrea PA, Bazin R, et al. Effect of factors unrelated to
tissue matching on corneal transplant endothelial rejection. Am J Ophthalmol. 1989; 107:647–
654. [PubMed: 2658619]
113. Sellami D, Abid S, Bouaouaja G, Ben Amor S, Kammoun B, et al. Epidemiology and risk factors
for corneal graft rejection. Transplant Proc. 2007; 39:2609–2611. [PubMed: 17954190]
114. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal
neovascularization. Invest Ophthalmol Vis Sci. 1996; 37:2485–2494. [PubMed: 8933765]
115. Polack FM. Scanning electron microscopy of the host-graft endothelial junction in corneal graft
reaction. Am J Ophthalmol. 1972; 73:704–710. [PubMed: 4555089]
Qazi and Hamrah Page 17
J Clin Cell Immunol. Author manuscript; available in PMC 2014 March 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t116. Polack FM. Scanning electron microscopy of corneal graft rejection: epithelial rejection,
endothelial rejection, and formation of posterior graft membranes. Invest Ophthalmol. 1972;
11:1–14. [PubMed: 4550101]
117. Polack FM, Kanai A. Electron microscopic studies of graft endothelium in corneal graft rejection.
Am J Ophthalmol. 1972; 73:711–717. [PubMed: 4555090]
118. Khodadoust, A. The allograft rejection reaction: the leading cause of late failure of clinical
corneal grafts. In: Porter, R.; Knight, J., editors. Ciba Foundation Symposium 15 - Corneal Graft
Failure; John Wiley & Sons, Ltd; Chichester, UK. 1973.
119. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations,
frequency, preoperative correlates, and treatment. Arch Ophthalmol. 1981; 99:599–604.
[PubMed: 7013739]
120. Port FK, Dykstra DM, Merion RM, Wolfe RA. Trends and results for organ donation and
transplantation in the United States, 2004. Am J Transplant. 2005; 5:843–849. [PubMed:
15760412]
121. Küchle M, Cursiefen C, Nguyen NX, Langenbucher A, Seitz B, et al. Risk factors for corneal
allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes
Arch Clin Exp Ophthalmol. 2002; 240:580–584. [PubMed: 12136292]
122. Thompson RW Jr, Price MO, Bowers PJ, Price FW Jr. Long-term graft survival after penetrating
keratoplasty. Ophthalmology. 2003; 110:1396–1402. [PubMed: 12867398]
123. Price FW Jr, Whitson WE, Collins KS, Marks RG. Five-year corneal graft survival. A large,
single-center patient cohort. Arch Ophthalmol. 1993; 111:799–805. [PubMed: 8512481]
124. Luengo-Gimeno F, Tan DT, Mehta JS. Evolution of deep anterior lamellar keratoplasty (DALK).
Ocul Surf. 2011; 9:98–110. [PubMed: 21545763]
125. Pantanelli SM, Sabesan R, Ching SS, Yoon G, Hindman HB. Visual performance with wave
aberration correction after penetrating, deep anterior lamellar, or endothelial keratoplasty. Invest
Ophthalmol Vis Sci. 2012; 53:4797–4804. [PubMed: 22700712]
126. Nielsen E, Hjortdal J. Visual acuity and contrast sensitivity after posterior lamellar keratoplasty.
Acta Ophthalmol. 2012; 90:756–760. [PubMed: 21834927]
127. Anshu A, Price MO, Price FW Jr. Risk of corneal transplant rejection significantly reduced with
Descemet’s membrane endothelial keratoplasty. Ophthalmology. 2012; 119:536–540. [PubMed:
22218143]
128. Saelens IE, Bleyen I, Bartels MC, Van Rij G. A posterior khodadoust line in a graft rejection
episode after descemet stripping automated endothelial keratoplasty. Cornea. 2011; 30:245–246.
[PubMed: 21045664]
129. Lee WB, Jacobs DS, Musch DC, Kaufman SC, Reinhart WJ, et al. Descemet’s stripping
endothelial keratoplasty: safety and outcomes: a report by the American Academy of
Ophthalmology. Ophthalmology. 2009; 116:1818–1830. [PubMed: 19643492]
130. Sarnicola V, Toro P, Sarnicola C, Sarnicola E, Ruggiero A. Long-term graft survival in deep
anterior lamellar keratoplasty. Cornea. 2012; 31:621–626. [PubMed: 22406938]
131. Söğütlü Sari E, Kubaloğlu A, Ünal M, Piñero Llorens D, Koytak A, et al. Penetrating keratoplasty
versus deep anterior lamellar keratoplasty: comparison of optical and visual quality outcomes. Br
J Ophthalmol. 2012; 96:1063–1067. [PubMed: 22718792]
132. Borderie VM, Guilbert E, Touzeau O, Laroche L. Graft rejection and graft failure after anterior
lamellar versus penetrating keratoplasty. Am J Ophthalmol. 2011; 151:1024–1029. [PubMed:
21489399]
133. Hamrah, P.; Mantopoulos, D.; Akhtar, J.; Djalilian, AR. Immunologically High-Risk Penetrating
Keratoplasty. In: Krachmer, J.; Mannis, MJ.; Jolland, EJ., editors. Cornea. 3rdedn.. St. Louis,
USA: Mosby; 2010. p. 1495-1510.
134. Costa DC, de Castro RS, Kara-Jose N. Case-control study of subconjunctival triamcinolone
acetonide injection vs intravenous methylprednisolone pulse in the treatment of endothelial
corneal allograft rejection. Eye (Lond). 2009; 23:708–714. [PubMed: 18820657]
135. Holland EJ, Bartlett JD, Paterno MR, Usner DW, Comstock TL. Effects of loteprednol/
tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers.
Cornea. 2008; 27:50–55. [PubMed: 18245967]
Qazi and Hamrah Page 18
J Clin Cell Immunol. Author manuscript; available in PMC 2014 March 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t136. Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection. Oral versus single pulse
therapy. Ophthalmology. 1991; 98:329–333. [PubMed: 2023754]
137. Hill JC, Ivey A. Corticosteroids in corneal graft rejection: double versus single pulse therapy.
Cornea. 1994; 13:383–388. [PubMed: 7995059]
138. McClellan K, Lai T, Grigg J, Billson F. Penetrating keratoplasty in children: visual and graft
outcome. Br J Ophthalmol. 2003; 87:1212–1214. [PubMed: 14507748]
139. Friedman, JN.; Kaiser, KK. Ocular Pharmacology. In: Friedman, JN.; Kaiser, KK., editors.
Essentials of Ophthalmology. Philadelphia: Elsevier Health Sciences; 2007. p. 294
140. Tandon R, Verma K, Chawla B, Sharma N, Titiyal JS, et al. Intravenous dexamethasone vs.
methylprednisolone pulse therapy in the treatment of acute endothelial graft rejection. Eye
(Lond). 2009; 23:635–639. [PubMed: 18292787]
141. Poon A, Constantinou M, Lamoureux E, Taylor HR. Topical Cyclosporin A in the treatment of
acute graft rejection: a randomized controlled trial. Clin Experiment Ophthalmol. 2008; 36:415–
421. [PubMed: 18939344]
142. Cosar CB, Laibson PR, Cohen EJ, Rapuano CJ. Topical cyclosporine in pediatric keratoplasty.
Eye Contact Lens. 2003; 29:103–107. [PubMed: 12695714]
143. Belin MW, Bouchard CS, Frantz S, Chmielinska J. Topical cyclosporine in high-risk corneal
transplants. Ophthalmology. 1989; 96:1144–1150. [PubMed: 2797718]
144. Birnbaum F, Böhringer D, Sokolovska Y, Sundmacher R, Reinhard T. Immunosuppression with
cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a
retrospective study. Transplantation. 2005; 79:964–968. [PubMed: 15849551]
145. Miller K, Huber C, Niederwieser D, Göttinger W. Successful engraftment of high-risk corneal
allografts with short-term immunosuppression with cyclosporine. Transplantation. 1988; 45:651–
653. [PubMed: 3279589]
146. Althaus C, Dagres E, Reinhard T, Christians U, Sundmacher R. Cyclosporin-A and its
metabolites in the anterior chamber after topical and systemic application as determined with
high-performance liquid chromatography-electrospray mass spectrometry. Ger J Ophthalmol.
1996; 5:189–194. [PubMed: 8854101]
147. Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy.
Ophthalmology. 1994; 101:128–133. [PubMed: 8302545]
148. Poon AC, Forbes JE, Dart JK, Subramaniam S, Bunce C, et al. Systemic cyclosporin A in high
risk penetrating keratoplasties: a case-control study. Br J Ophthalmol. 2001; 85:1464–1469.
[PubMed: 11734522]
149. Shimazaki J, Den S, Omoto M, Satake Y, Shimmura S, et al. Prospective, randomized study of
the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol.
2011; 152:33–39. [PubMed: 21570054]
150. Perry HD, Donnenfeld ED, Acheampong A, Kanellopoulos AJ, Sforza PD, et al. Topical
Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced
ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea
and anterior chamber. CLAO J. 1998; 24:159–165. [PubMed: 9684074]
151. Reinhard T, Mayweg S, Reis A, Sundmacher R. Topical FK506 as immunoprophylaxis after
allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study. Transpl Int.
2005; 18:193–197. [PubMed: 15691272]
152. Dhaliwal JS, Mason BF, Kaufman SC. Long-term use of topical tacrolimus (FK506) in high-risk
penetrating keratoplasty. Cornea. 2008; 27:488–493. [PubMed: 18434855]
153. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and
limbal grafts. Ophthalmology. 2001; 108:1838–1844. [PubMed: 11581059]
154. Joseph A, Raj D, Shanmuganathan V, Powell RJ, Dua HS. Tacrolimus immunosuppression in
high-risk corneal grafts. Br J Ophthalmol. 2007; 91:51–55. [PubMed: 16956911]
155. Reis A, Reinhard T, Voiculescu A, Kutkuhn B, Godehardt E, et al. Mycophenolate mofetil versus
cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J
Ophthalmol. 1999; 83:1268–1271. [PubMed: 10535855]
156. Reinhard T, Mayweg S, Sokolovska Y, Seitz B, Mittelviefhaus H, et al. Systemic mycophenolate
mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an
Qazi and Hamrah Page 19
J Clin Cell Immunol. Author manuscript; available in PMC 2014 March 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tongoing prospectively randomized multicentre study. Transpl Int. 2005; 18:703–708. [PubMed:
15910297]
157. Bachmann B, Taylor RS, Cursiefen C. Corneal neovascularization as a risk factor for graft failure
and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology. 2010;
117:1300–1305. [PubMed: 20605214]
158. Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization. Pathogenesis
and inhibition. Cornea. 1987; 6:250–257. [PubMed: 2446823]
159. Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest
Ophthalmol Vis Sci. 2000; 41:2148–2153. [PubMed: 10892856]
160. Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, et al. Corneal avascularity is due to soluble
VEGF receptor-1. Nature. 2006; 443:993–997. [PubMed: 17051153]
161. Cursiefen C, Maruyama K, Jackson DG, Streilein JW, Kruse FE. Time course of angiogenesis
and lymphangiogenesis after brief corneal inflammation. Cornea. 2006; 25:443–447. [PubMed:
16670483]
162. Dana MR. Angiogenesis and lymphangiogenesis-implications for corneal immunity. Semin
Ophthalmol. 2006; 21:19–22. [PubMed: 16517440]
163. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes
Arch Clin Exp Ophthalmol. 2007; 245:1577–1579. [PubMed: 17458556]
164. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab
injection for corneal neovascularization. Cornea. 2008; 27:142–147. [PubMed: 18216566]
165. Benayoun Y, Adenis JP, Casse G, Forte R, Robert PY. Effects of subconjunctival bevacizumab
on corneal neovascularization: results of a prospective study. Cornea. 2012; 31:937–944.
[PubMed: 22357391]
166. Symes RJ, Poole TR. Corneal graft surgery combined with subconjunctival bevacizumab
(avastin). Cornea. 2010; 29:691–693. [PubMed: 20458243]
167. Harooni H, Reddy V, Root T, Ambati B. Bevacizumab for graft rejection. Ophthalmology. 2007;
114:1950. [PubMed: 17908597]
168. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, et al. Bevacizumab as a potent inhibitor
of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;
48:2545–2552. [PubMed: 17525183]
169. Detry B, Blacher S, Erpicum C, Paupert J, Maertens L, et al. Sunitinib inhibits inflammatory
corneal lymphangiogenesis. Invest Ophthalmol Vis Sci. 2013; 54:3082–3093. [PubMed:
23580490]
170. Cho YK, Zhang X, Uehara H, Young JR, Archer B, et al. Vascular Endothelial Growth Factor
Receptor 1 morpholino increases graft survival in a murine penetrating keratoplasty model.
Invest Ophthalmol Vis Sci. 2012; 53:8458–8471. [PubMed: 23150613]
171. Zhu SN, Yamada J, Streilein JW, Dana MR. ICAM-1 deficiency suppresses host allosensitization
and rejection of MHC-disparate corneal transplants. Transplantation. 2000; 69:1008–1013.
[PubMed: 10755569]
172. Hori J, Yamagami S, Obata H, Tsuru T, Isobe M. Effect of monoclonal antibody to VLA-4 on
corneal allograft survival in mice. Transplant Proc. 1996; 28:1990–1991. [PubMed: 8658970]
173. Hori J, Isobe M, Yamagami S, Mizuochi T, Tsuru T. Specific immunosuppression of corneal
allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice.
Exp Eye Res. 1997; 65:89–98. [PubMed: 9237869]
174. Birnbaum F, Reis A, Böhringer D, Sokolowska Y, Mayer K, et al. An open prospective pilot
study on the use of rapamycin after penetrating highrisk keratoplasty. Transplantation. 2006;
81:767–772. [PubMed: 16534481]
175. Chatel MA, Larkin DF. Sirolimus and mycophenolate as combination prophylaxis in corneal
transplant recipients at high rejection risk. Am J Ophthalmol. 2010; 150:179–184. [PubMed:
20570235]
176. Ippoliti G, Fronterrè A. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment
of acute corneal graft rejection. Transplant Proc. 1989; 21:3133–3134. [PubMed: 2523173]
177. Ippoliti G, Fronterrè A. Use of locally injected anti-T monoclonal antibodies in the treatment of
acute corneal graft rejection. Transplant Proc. 1987; 19:2579–2580. [PubMed: 3274568]
Qazi and Hamrah Page 20
J Clin Cell Immunol. Author manuscript; available in PMC 2014 March 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t178. Schmitz K, Hitzer S, Behrens-Baumann W. Immune suppression by combination therapy with
basiliximab and cyclosporin in high risk keratoplasty. A pilot study. Ophthalmologe. 2002;
99:38–45. [PubMed: 11840795]
179. Birnbaum F, Jehle T, Schwartzkopff J, Sokolovska Y, Böhringer D, et al. Basiliximab following
penetrating risk-keratoplasty--a prospective randomized pilot study. Klin Monbl Augenheilkd.
2008; 225:62–65. [PubMed: 18236372]
180. Jun AS, Larkin DF. Prospects for gene therapy in corneal disease. Eye (Lond). 2003; 17:906–911.
[PubMed: 14631395]
181. Hoffmann F, Zhang EP, Pohl T, Kunzendorf U, Wachtlin J, et al. Inhibition of corneal allograft
reaction by CTLA4-Ig. Graefes Arch Clin Exp Ophthalmol. 1997; 235:535–540. [PubMed:
9285225]
182. König Merediz SA, Zhang EP, Wittig B, Hoffmann F. Ballistic transfer of minimalistic
immunologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in
mice after orthotopic corneal allograft transplantation. Graefes Arch Clin Exp Ophthalmol. 2000;
238:701–707. [PubMed: 11011692]
183. Thiel MA, Steiger JU, O’Connell PJ, Lehnert AM, Coster DJ, et al. Local or short-term systemic
costimulatory molecule blockade prolongs rat corneal allograft survival. Clin Exp Ophthalmol.
2005; 33:176–180.
184. Gebhardt BM, Hodkin M, Varnell ED, Kaufman HE. Protection of corneal allografts by CTLA4-
Ig. Cornea. 1999; 18:314–320. [PubMed: 10336035]
185. Qian Y, Boisgerault F, Benichou G, Dana MR. Blockade of CD40–CD154 costimulatory pathway
promotes survival of allogeneic corneal transplants. Invest Ophthalmol Vis Sci. 2001; 42:987–
994. [PubMed: 11274076]
186. Qian Y, Dana MR. Effect of locally administered anti-CD154 (CD40 ligand) monoclonal
antibody on survival of allogeneic corneal transplants. Cornea. 2002; 21:592–597. [PubMed:
12131037]
187. Watson MP, George AJ, Larkin DF. Differential effects of costimulatory pathway modulation on
corneal allograft survival. Invest Ophthalmol Vis Sci. 2006; 47:3417–3422. [PubMed: 16877411]
Qazi and Hamrah Page 21
J Clin Cell Immunol. Author manuscript; available in PMC 2014 March 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t